Leerink Partnrs Brokers Reduce Earnings Estimates for IPSC

Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) - Equities researchers at Leerink Partnrs reduced their Q2 2025 earnings per share estimates for shares of Century Therapeutics in a research note issued on Monday, May 19th. Leerink Partnrs analyst D. Graybosch now forecasts that the company will post earnings of ($0.37) per share for the quarter, down from their previous forecast of ($0.14). The consensus estimate for Century Therapeutics' current full-year earnings is ($1.61) per share. Leerink Partnrs also issued estimates for Century Therapeutics' Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($0.13) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($1.27) EPS, FY2026 earnings at ($1.27) EPS, FY2027 earnings at ($1.25) EPS, FY2028 earnings at ($0.98) EPS and FY2029 earnings at ($0.87) EPS.

Century Therapeutics (NASDAQ:IPSC - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported $0.89 earnings per share for the quarter, beating the consensus estimate of ($0.31) by $1.20. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%. The company had revenue of $109.16 million for the quarter, compared to analysts' expectations of $45.52 million.

IPSC has been the topic of several other research reports. HC Wainwright lowered their target price on Century Therapeutics from $5.00 to $2.00 and set a "buy" rating on the stock in a research note on Thursday, April 3rd. Piper Sandler reduced their price target on Century Therapeutics from $4.00 to $2.00 and set an "overweight" rating for the company in a report on Thursday, March 20th. Chardan Capital reduced their price target on Century Therapeutics from $7.00 to $6.00 and set a "buy" rating for the company in a report on Friday, May 16th. Finally, Guggenheim reiterated a "buy" rating on shares of Century Therapeutics in a report on Friday, March 28th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $4.20.

Century Therapeutics Trading Down 2.7%

NASDAQ:IPSC traded down $0.02 on Wednesday, hitting $0.56. 426,222 shares of the company's stock traded hands, compared to its average volume of 475,206. Century Therapeutics has a 1 year low of $0.34 and a 1 year high of $3.46. The firm has a 50-day moving average price of $0.51 and a 200-day moving average price of $0.84. The company has a market cap of $48.15 million, a PE ratio of -0.30 and a beta of 1.80.

Institutional Investors Weigh In On Century Therapeutics

Several institutional investors have recently made changes to their positions in IPSC. Marshall Wace LLP acquired a new stake in shares of Century Therapeutics during the 4th quarter valued at about $36,000. Jane Street Group LLC lifted its holdings in Century Therapeutics by 166.2% in the 4th quarter. Jane Street Group LLC now owns 48,036 shares of the company's stock worth $49,000 after purchasing an additional 29,992 shares during the last quarter. Two Sigma Advisers LP acquired a new stake in Century Therapeutics in the 4th quarter worth approximately $52,000. Sei Investments Co. acquired a new stake in Century Therapeutics in the 4th quarter worth approximately $53,000. Finally, AQR Capital Management LLC lifted its holdings in Century Therapeutics by 358.9% in the 1st quarter. AQR Capital Management LLC now owns 111,079 shares of the company's stock worth $53,000 after purchasing an additional 86,875 shares during the last quarter. 50.20% of the stock is currently owned by institutional investors and hedge funds.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.